A Smart + Strong Site
Subscribe to:
• E-newsletters
• POZ magazine
POZ Personals
Sign In / Join		 Username:
 Password:
Back to home » Top Stories » CROI 2009
CROI 2009 16th Conference on Retroviruses and Opportunistic Infections
Montréal, Canada
February 8-11, 2009

Antiretroviral Highlights from CROI

February 20, 2009

At the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal, David Evans talks with Tony Mills, MD, a private practice physician and researcher at the University of California in Los Angeles, about the latest in antiretroviral research. Dr. Mills gives his take on the surprising results of an Isentress (raltegravir) clinical trial, the latest news from Gilead about their four-in-one pill, and the promise of viral eradication.

 


7 1/2 minutes. Click here for the transcript.

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       

More from CROI 2009

HIV/AIDS Complications

March 4, 2009
HIV and Women
February 26, 2009
HIV and the Brain: What to Watch Out For
February 25, 2009
HIV and Cancer: Prevalence and Prevention
February 23, 2009
Half of Deaths in People With HIV No Longer From AIDS
February 20, 2009
Testosterone Therapy: Good for Women Too
Lymphoma: Death Rates Still High, but Cancer May Be Predicted
February 19, 2009
Quarter of U.S. Positive Women Not Receiving Annual Pap Smears
February 18, 2009
HDL and Small HDL Particles Predict Cardio Problems in HIV
Scientists Still Seeking Clues to Abacavir Heart Attack Mystery
February 17, 2009
Smoking Cessation: Hispanics, Nicotine Patch Users Do Best
Nerve Damage Is a Common Problem in People With HIV
February 11, 2009
PIs, Abacavir and Cardiovascular Disease: What’s the Risk?
D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival
HIV Itself Is a Major Heart Disease Risk Factor
February 10, 2009
Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIV
February 9, 2009
Diabetes Drug Avandia Helps Reverse Lipoatrophy

HIV Transmission and Prevention

February 27, 2009
Prevention Highlights, Part 1: PrEP
Prevention Highlights, Part 2: Treatment as Prevention
February 13, 2009
Microbicides Make a Comeback
February 9, 2009
HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmission

Starting and Switching Treatment

February 12, 2009
Isentress Shows Long-Term Benefits in Treatment-Experienced Patients
Antidepressants Improve Viral Load Response to Treatment Due to Better Adherence
February 10, 2009
Start HIV Treatment Early—But When?
February 9, 2009
Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Risk

Experimental HIV Drugs

February 20, 2009
Antiretroviral Highlights from CROI
February 10, 2009
IL-2 Fails in Two Large Studies
February 9, 2009
GS 9350 and SPI-452: Emerging Alternatives to Norvir Boosting


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.